Jacob S Lipkin Syed M Rizvi Zoran Gatalica Nabeel E Sarwani Sheldon L Holder Mathew Kaag Joseph J Drabick Monika Joshi
10.4161/15384047.2014.972843
Cancer Biol Ther
2015;16(1):28-33.
mtor pten rrm1 cisplatin everolimus maintenance-therapy renal medullary carcinoma
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/25692619/
Carcinoma, Medullary / drug therapy Carcinoma, Medullary / genetics Carcinoma, Renal Cell / drug therapy Carcinoma, Renal Cell / genetics Genetic Variation PTEN Phosphohydrolase / genetics Protein Kinase Inhibitors / therapeutic use
Carcinoma, Medullary / drug therapy Carcinoma, Medullary / genetics Carcinoma, Renal Cell / drug therapy Carcinoma, Renal Cell / genetics Genetic Variation PTEN Phosphohydrolase / genetics Protein Kinase Inhibitors / therapeutic use Case Reports Adult Antineoplastic Combined Chemotherapy Protocols / therapeutic use Biopsy Carcinoma, Medullary / diagnosis Carcinoma, Renal Cell / diagnosis Gene Expression Humans Male PTEN Phosphohydrolase / metabolism Protein Kinase Inhibitors / pharmacology Ribonucleoside Diphosphate Reductase TOR Serine-Threonine Kinases / antagonists & inhibitors Tomography, X-Ray Computed Treatment Outcome Tumor Suppressor Proteins / genetics Tumor Suppressor Proteins / metabolism Protein Kinase Inhibitors Tumor Suppressor Proteins RRM1 protein, human Ribonucleoside Diphosphate Reductase TOR Serine-Threonine Kinases PTEN Phosphohydrolase
PMC4622500
25692619
Therapeutic approach guided by genetic alteration: use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression
2015